<p>Bicycle Therapeutics plc（納斯達克代碼：BCYC - 獲取免費報告）在四月份遭遇了空頭頭寸的大幅下降。截至四月十五日，空頭頭寸總計為 3,130,000 股，較三月三十一日的 4,300,000 股下降了 27.2%。該公司的約 5.0% 的股份被做空。根據平均每日交易量 349,300 股，目前的覆蓋天數比率為 9.0 天。</p>
<p>獲取 <strong>Bicycle Therapeutics</strong> 警報：</p>
<h2>分析師評級上調與下調</h2>
<p>幾位分析師最近對 BCYC 股票發佈了報告。Stephens 在 1 月 22 日的研究報告中重申了 “持平” 的評級，並對 Bicycle Therapeutics 的股票設定了 15.00 美元的目標價。Needham &amp; Company LLC 在 4 月 9 日的研究報告中重申了 “買入” 評級，並將 Bicycle Therapeutics 的目標價設定為 30.00 美元。最後，HC Wainwright 在 2 月 26 日的研究報告中重申了 “買入” 評級，並對 Bicycle Therapeutics 的股票設定了 33.00 美元的目標價。兩位研究分析師對該股票給予了持有評級，六位分析師給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 29.14 美元。</p>
<p><strong>獲取我們關於 BCYC 的最新研究報告</strong></p>
<h2>Bicycle Therapeutics 股票表現</h2>
<p>納斯達克 BCYC 的股票在週四開盤價為 8.56 美元。該公司的市值為 5.9237 億美元，市盈率為-2.60，貝塔值為 1.40。Bicycle Therapeutics 的 52 周低點為 6.10 美元，52 周高點為 28.67 美元。該公司的 50 日移動平均價格為 8.79 美元，200 日移動平均價格為 14.72 美元。</p>
<p>Bicycle Therapeutics（納斯達克代碼：BCYC - 獲取免費報告）最近於 2 月 25 日發佈了季度財報。該公司報告每股收益（EPS）為（0.75 美元），超出分析師的共識預期（0.85 美元）0.10 美元。該公司本季度的收入為 370 萬美元，而共識預期為 547 萬美元。Bicycle Therapeutics 的淨利潤率為-450.64%，股本回報率為-27.35%。該公司本季度的收入同比下降了 30.2%。在去年同期，該公司每股收益為（1.16 美元）。分析師預測 Bicycle Therapeutics 在當前年度的每股收益將為-3.06 美元。</p>
<h2>機構資金流入與流出</h2>
<p>機構投資者最近調整了對該股票的持有。巴克萊銀行在第四季度將其在 Bicycle Therapeutics 的持股比例提高了 878.3%。巴克萊銀行目前持有該公司 2,612 股股票，價值 37,000 美元，此前在此期間增持了 2,345 股。Avior Wealth Management LLC 在第四季度新購入了 Bicycle Therapeutics 的股份，價值 57,000 美元。GAMMA Investing LLC 在第一季度將其在 Bicycle Therapeutics 的持股比例提高了 879.5%。GAMMA Investing LLC 目前持有該公司 8,982 股股票，價值 76,000 美元，此前在上個季度增持了 8,065 股。Exchange Traded Concepts LLC 在第一季度將其在 Bicycle Therapeutics 的持股比例提高了 90.3%。Exchange Traded Concepts LLC 目前持有該公司 12,764 股股票，價值 108,000 美元，此前在上個季度增持了 6,057 股。最後，Cerity Partners LLC 在第一季度新購入了 Bicycle Therapeutics 的股份，價值 113,000 美元。機構投資者和對沖基金持有該公司 86.15% 的股票。</p>
<h2>Bicycle Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Bicycle Therapeutics plc 是一家臨牀階段的生物製藥公司，開發一類針對美國和英國現有治療手段未能滿足的疾病的藥物。其產品管線包括 BT8009，一種正在進行 I/II/III 期臨牀試驗的自行車毒素結合物（BTC），用於治療高 nectin-4 表達的腫瘤；BT5528，一種正在進行 I/II 期臨牀試驗的 BTC，用於治療 Ephrin A 型受體 2 表達的腫瘤；BT7480，一種正在進行 I/II 期的自行車 TICA 分子，針對 Nectin-4 並激活 CD137；以及 BT7455，一種針對 Ephrin A 型受體 2 和 CD137 的自行車 TICA 分子，目前處於臨牀前試驗階段。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Bicycle Therapeutics 更好</li>
<li>你應該投資於便士股票嗎？</li>
<li>D-Wave 與 Davidson 的項目為何會改變量子計算遊戲</li>
<li>關於 Markup 計算器</li>
<li>Hims &amp; Hers 股票因與諾和諾德的合作而飆升</li>
<li>10 美元以下的最佳股票</li>
<li>亞馬遜的收益將決定股票的反彈成敗</li>
</ul>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Bicycle Therapeutics 嗎？</h2>
<p>在你考慮 Bicycle Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Bicycle Therapeutics 並不在名單上。</p>
<p>雖然 Bicycle Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

BCYC

<p>Bicycle Therapeutics plc（納斯達克代碼：BCYC）在空頭頭寸方面經歷了顯著下降，截至 4 月 15 日，下降了 27.2%，降至 3,130,000 股。目前，該公司的股票中有 5.0% 被做空，基於每日平均成交量 349,300 股，覆蓋天數比率為 9.0 天。分析師的評級意見不一，普遍評級為 “適度買入”，平均目標價為 29.14 美元。該公司報告的季度每股收益為（$0.75），超出預期，但收入同比下降了 30.2%。機構投資者持有 86.15% 的股份</p>

<p>Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) was the target of a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 3,130,000 shares, a decline of 27.2% from the March 31st total of 4,300,000 shares. Approximately 5.0% of the shares of the company are sold short. Based on an average daily volume of 349,300 shares, the days-to-cover ratio is currently 9.0 days.</p>
<div class="lb-trans"><p>Bicycle Therapeutics plc（納斯達克代碼：BCYC - 獲取免費報告）在四月份遭遇了空頭頭寸的大幅下降。截至四月十五日，空頭頭寸總計為 3,130,000 股，較三月三十一日的 4,300,000 股下降了 27.2%。該公司的約 5.0% 的股份被做空。根據平均每日交易量 349,300 股，目前的覆蓋天數比率為 9.0 天。</p>
</div><p>Get <strong>Bicycle Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Bicycle Therapeutics</strong> 警報：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>Several analysts recently issued reports on BCYC shares. Stephens restated an &#34;equal weight&#34; rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and set a $30.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, April 9th. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $29.14.</p>
<div class="lb-trans"><p>幾位分析師最近對 BCYC 股票發佈了報告。Stephens 在 1 月 22 日的研究報告中重申了 “持平” 的評級，並對 Bicycle Therapeutics 的股票設定了 15.00 美元的目標價。Needham &amp; Company LLC 在 4 月 9 日的研究報告中重申了 “買入” 評級，並將 Bicycle Therapeutics 的目標價設定為 30.00 美元。最後，HC Wainwright 在 2 月 26 日的研究報告中重申了 “買入” 評級，並對 Bicycle Therapeutics 的股票設定了 33.00 美元的目標價。兩位研究分析師對該股票給予了持有評級，六位分析師給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 29.14 美元。</p>
</div><p><strong>Get Our Latest Research Report on BCYC</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 BCYC 的最新研究報告</strong></p>
</div><h2>Bicycle Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 股票表現</h2>
</div><p>Shares of NASDAQ BCYC opened at $8.56 on Thursday. The company has a market capitalization of $592.37 million, a P/E ratio of -2.60 and a beta of 1.40. Bicycle Therapeutics has a 52-week low of $6.10 and a 52-week high of $28.67. The company's 50 day moving average price is $8.79 and its 200-day moving average price is $14.72.</p>
<div class="lb-trans"><p>納斯達克 BCYC 的股票在週四開盤價為 8.56 美元。該公司的市值為 5.9237 億美元，市盈率為-2.60，貝塔值為 1.40。Bicycle Therapeutics 的 52 周低點為 6.10 美元，52 周高點為 28.67 美元。該公司的 50 日移動平均價格為 8.79 美元，200 日移動平均價格為 14.72 美元。</p>
</div><p>Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.10. The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company's revenue for the quarter was down 30.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.16) EPS. Analysts forecast that Bicycle Therapeutics will post -3.06 earnings per share for the current year.</p>
<div class="lb-trans"><p>Bicycle Therapeutics（納斯達克代碼：BCYC - 獲取免費報告）最近於 2 月 25 日發佈了季度財報。該公司報告每股收益（EPS）為（0.75 美元），超出分析師的共識預期（0.85 美元）0.10 美元。該公司本季度的收入為 370 萬美元，而共識預期為 547 萬美元。Bicycle Therapeutics 的淨利潤率為-450.64%，股本回報率為-27.35%。該公司本季度的收入同比下降了 30.2%。在去年同期，該公司每股收益為（1.16 美元）。分析師預測 Bicycle Therapeutics 在當前年度的每股收益將為-3.06 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入與流出</h2>
</div><p>Institutional investors have recently modified their holdings of the stock. Barclays PLC lifted its position in shares of Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after acquiring an additional 2,345 shares during the period. Avior Wealth Management LLC acquired a new position in Bicycle Therapeutics during the fourth quarter worth $57,000. GAMMA Investing LLC raised its holdings in Bicycle Therapeutics by 879.5% during the first quarter. GAMMA Investing LLC now owns 8,982 shares of the company's stock worth $76,000 after buying an additional 8,065 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Bicycle Therapeutics by 90.3% in the 1st quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock worth $108,000 after acquiring an additional 6,057 shares in the last quarter. Finally, Cerity Partners LLC bought a new stake in shares of Bicycle Therapeutics in the 1st quarter worth $113,000. Institutional investors and hedge funds own 86.15% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近調整了對該股票的持有。巴克萊銀行在第四季度將其在 Bicycle Therapeutics 的持股比例提高了 878.3%。巴克萊銀行目前持有該公司 2,612 股股票，價值 37,000 美元，此前在此期間增持了 2,345 股。Avior Wealth Management LLC 在第四季度新購入了 Bicycle Therapeutics 的股份，價值 57,000 美元。GAMMA Investing LLC 在第一季度將其在 Bicycle Therapeutics 的持股比例提高了 879.5%。GAMMA Investing LLC 目前持有該公司 8,982 股股票，價值 76,000 美元，此前在上個季度增持了 8,065 股。Exchange Traded Concepts LLC 在第一季度將其在 Bicycle Therapeutics 的持股比例提高了 90.3%。Exchange Traded Concepts LLC 目前持有該公司 12,764 股股票，價值 108,000 美元，此前在上個季度增持了 6,057 股。最後，Cerity Partners LLC 在第一季度新購入了 Bicycle Therapeutics 的股份，價值 113,000 美元。機構投資者和對沖基金持有該公司 86.15% 的股票。</p>
</div><h2>Bicycle Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.</p>
<div class="lb-trans"><p>Bicycle Therapeutics plc 是一家臨牀階段的生物製藥公司，開發一類針對美國和英國現有治療手段未能滿足的疾病的藥物。其產品管線包括 BT8009，一種正在進行 I/II/III 期臨牀試驗的自行車毒素結合物（BTC），用於治療高 nectin-4 表達的腫瘤；BT5528，一種正在進行 I/II 期臨牀試驗的 BTC，用於治療 Ephrin A 型受體 2 表達的腫瘤；BT7480，一種正在進行 I/II 期的自行車 TICA 分子，針對 Nectin-4 並激活 CD137；以及 BT7455，一種針對 Ephrin A 型受體 2 和 CD137 的自行車 TICA 分子，目前處於臨牀前試驗階段。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Bicycle Therapeutics</li>
<li>Should You Invest in Penny Stocks?</li>
<li>Why D-Wave's Project With Davidson Is a Game-Changer For Quantum</li>
<li>About the Markup Calculator</li>
<li>Hims &amp; Hers Stock Soars on Novo Nordisk Collaboration</li>
<li>Best Stocks Under $10.00</li>
<li>Amazon's Earnings Will Make or Break the Stock's Comeback</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Bicycle Therapeutics 更好</li>
<li>你應該投資於便士股票嗎？</li>
<li>D-Wave 與 Davidson 的項目為何會改變量子計算遊戲</li>
<li>關於 Markup 計算器</li>
<li>Hims &amp; Hers 股票因與諾和諾德的合作而飆升</li>
<li>10 美元以下的最佳股票</li>
<li>亞馬遜的收益將決定股票的反彈成敗</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bicycle Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Bicycle Therapeutics 嗎？</h2>
</div><p>Before you consider Bicycle Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Bicycle Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Bicycle Therapeutics 並不在名單上。</p>
</div><p>While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Bicycle Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Bicycle Therapeutics plc（NASDAQ:BCYC）的空頭頭寸顯著下降